246 related articles for article (PubMed ID: 30528653)
1. Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
Dearnaley D; Griffin CL; Lewis R; Mayles P; Mayles H; Naismith OF; Harris V; Scrase CD; Staffurth J; Syndikus I; Zarkar A; Ford DR; Rimmer YL; Horan G; Khoo V; Frew J; Venkitaraman R; Hall E
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):605-617. PubMed ID: 30528653
[TBL] [Abstract][Full Text] [Related]
2. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
3. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial.
Katayama S; Habl G; Kessel K; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2014 Jan; 14():20. PubMed ID: 24422782
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study.
Guerrero Urbano T; Khoo V; Staffurth J; Norman A; Buffa F; Jackson A; Adams E; Hansen V; Clark C; Miles E; McNair H; Nutting C; Parker C; Eeles R; Huddart R; Horwich A; Dearnaley DP
Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):236-44. PubMed ID: 20171852
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
Reis Ferreira M; Khan A; Thomas K; Truelove L; McNair H; Gao A; Parker CC; Huddart R; Bidmead M; Eeles R; Khoo V; van As NJ; Hansen VN; Dearnaley DP
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1234-1242. PubMed ID: 28939224
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes.
Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study.
Parry MG; Sujenthiran A; Cowling TE; Nossiter J; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
J Clin Oncol; 2019 Jul; 37(21):1828-1835. PubMed ID: 31163009
[TBL] [Abstract][Full Text] [Related]
9. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
[TBL] [Abstract][Full Text] [Related]
10. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
12. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition.
Ganswindt U; Paulsen F; Corvin S; Eichhorn K; Glocker S; Hundt I; Birkner M; Alber M; Anastasiadis A; Stenzl A; Bares R; Budach W; Bamberg M; Belka C
BMC Cancer; 2005 Jul; 5():91. PubMed ID: 16048656
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
14. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
17. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
[TBL] [Abstract][Full Text] [Related]
18. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
[TBL] [Abstract][Full Text] [Related]
20. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
